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Northwestern blot analysis in the presence of competitor RNA was used to examine the interaction between
the mouse hepatitis virus (MHV) nucleocapsid protein (N) and virus-specific RNAs. Our accompanying article
demonstrates that anti-N monoclonal antibodies immunoprecipitated all seven MHV-specific RNAs as well as
the small leader-containing RNAs from infected cells. In this article we report that a Northwestern blotting
protocol using radiolabeled viral RNAs in the presence of host cell competitor RNA can be used to demonstrate
a high-affinity interaction between the MHV N protein and the virus-specific RNAs. Further, RNA probes
prepared by in vitro transcription were used to define the sequences that participate in such high-affinity
binding. A specific interaction occurs between the N protein and sequences contained with the leader RNA
which is conserved at the 5' end of all MHV RNAs. We have further defined the binding sites to the area of
nucleotides 56 to 65 at the 3' end of the leader RNA and suggest that this interaction may play an important
role in the discontinuous nonprocessive RNA transcriptional process unique to coronaviruses.
The murine coronavirus mouse hepatitis virus (MHV)
contains a single-stranded positive-polarity RNA of approx-
imately 6 x 106 daltons (20). This RNA interacts with the
60,000-dalton nucleocapsid (N) protein to form a helical
nucleocapsid structure (34). The MHV envelope contains
two virus-specified envelope glycoproteins, designated El
and E2, which are acquired during maturation at intracyto-
plasmic membranes (34). E2 is a 180,000-dalton N-linked
glycoprotein which mediates cell-cell fusion and is the site of
neutralizing-antibody attachment (13, 15, 35). El is an 0-
linked matrix glycoprotein of 23,000 daltons that is believed
to interact with N in the formation of virions (34, 35).
Genomic-length mRNA and six subgenomic mRNAs are
transcribed from a full-length negative-stranded template
(19, 31). These intracellular mRNAs are both capped and
polyadenylated and are arranged in the form of a nested-set
array from the 3' end of the genome, i.e., they have common
3' termini and extend for various lengths in the 5' direction
(18, 31). In addition, each virus-specific mRNA contains an
identical leader sequence approximately 72 nucleotides long
which is derived from the 5' end of genomic RNA (17, 18).
After synthesis, the leader RNA disassociates from the
negative-stranded template and rebinds at the initiation sites
for each of the six subgenomic mRNAs, thereby serving as a
primer for transcription (6, 8, 22). Transcription of the MHV
mRNAs is discontinuous, and pausing occurs in AU-rich
regions or regions of secondary structure (6). This leads to
the generation of discrete small leader-containing RNAs
which are present both as nascent plus-strands on the
replicative intermediate (RI) RNA and as free molecules
dissociated from the transcript complex. RNA species orig-
inate during synthesis of the individual genes, with 3' termi-
nation corresponding to regions of the RNA with secondary
structure or AU-rich regions (6). These discrete functional
intermediate RNAs probably also function in trans as inter-
mediates of RNA-RNA recombination (22).
* Corresponding author.
In the accompanying article we have shown that MHV
virion RNA as well as all seven intracellular RNAs are
complexed with the N protein (5). Immunoprecipitation of
the small leader-containing RNA species from infected cells
demonstrated that the leader RNA sequences were sufficient
to bind the N protein. Our inability to demonstrate N
complexed to leader RNAs of less than 57 nucleotides along
with its presence on RNAs of greater than 65 nucleotides
suggested that either the N-RNA binding site was encoded
within this 10-nucleotide stretch or there was a minimum-
size constraint on the N-RNA interaction. In addition, the
data suggested that N protein is associated with the RI RNA
complex in infected cells. This may be due to the presence of
N protein associated with the leader RNA sequences at the
5' end of the nascent strands; however, we could not
determine whether N bound the negative-stranded RNA
directly via antisense leader RNA sequences. In this report,
we describe the use of competitor RNA in a Northwestern
blot analysis to identify high-affinity RNA-protein interac-
tions and present additional evidence for the specificity ofN
binding to the leader segment of MHV RNA. Previous
studies using this assay in the absence of competitor RNA
were unable to detect sequence-specific binding of the N
protein (26). This assay was used to distinguish between
binding to the positive- and negative-stranded RNAs and
provides additional evidence which suggests that N protein
binds to leader RNA between nucleotides 56 and 65 from the
5' end of all the MHV mRNAs.
MATERIALS AND METHODS
Virus and cells. The studies described used the A59 strain
of MHV. Virus was propagated in the DBT murine astrocy-
toma cell line or L2 cells as previously described (20). Cells
were grown in 150- or 100-mm-diameter petri plates (Becton
Dickinson Labware, Oxnard, Calif.) and infected at a mul-
tiplicity of infection of 1 to 5. For experiments using 32p; to
radiolabel MHV-specific mRNAs, infected cells were
treated with 2 Rg of actinomycin D per ml at 2.5 h postin-
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FIG. 1. Structure of the MHV cDNA probes used for North-
western blot experiments. (A) Clone pF82P contains nucleotides 5
through 1149 derived from the 5' end of the genome. Clone F82D is
derived from F82P and contains nucleotides 56 through 1149 from
the 5' end of the genome. Clone F82N is derived from cDNA clone
F82 and contains nucleotides 187 through 1989 from the 5' end of the
genome. (B) Clone E1-L contains the leader RNA (nucleotides 1
through 90) derived from the 5' end of mRNA 6 (gene F). Clone
E1-500 lacks the leader RNA (nucleotides 90 through 609) and is
derived from the 5' end ofmRNA 6. (C) The derivation of the 24 and
56 nucleotide RNAs synthesized from E1-L after digestion with
either SnaBI or DraI.
fection (p.i.) and labeled with 500 p.Ci of 32p; (ICN Pharma-
ceuticals Inc., Irvine, Calif.) at 4.5 h p.i. RNA was harvested
by phenol extraction of nucleus-free lysates of infected cells
at 7.5 to 8.5 h p.i.
In vitro transcription ofMHV strand-specific probes. The in
vitro transcripts used in this study were derived from pT7
plasmids containing the bacterial T7 RNA polymerase initi-
ation site. Inserts were obtained by cDNA cloning of either
the A59 or JHM strains of MHV and are depicted in Fig. 1.
The E1-L' plasmids were obtained from the 5' end of gene F
of A59 virus by subcloning a BamHI-DdeI fragment into the
BamHI site of pT7.1 or pT7.2. These constructs contain the
72-base leader plus 18 bases extending into the El coding
region (2). The plasmid E1-L'(+) synthesizes RNA in the
plus-stranded configuration, while the plasmid E1-L'(-)
synthesizes the identical sequences in the negative-sense
configuration. Plasmid E1-500 contains the coding region of
gene F without the leader RNA sequences (nucleotides 90 to
609) and synthesizes plus-stranded RNA from the T7 pro-
moter (5, 6).
Details of the construction of pT7F82P (F82P), pT7F82D
(F82D), and pT7F82N (F82N) have been previously de-
scribed (28, 30). Briefly, plasmid F82P contains the initial 1.2
kilobases of nucleotides from the 5' end of genomic RNA,
including all but 5 nucleotides from the 5' end of the leader
sequence. Plasmid F82P(+) produces RNA in the plus-
stranded configuration, while plasmid F82P(-) contains the
identical insert in the opposite orientation and produces
negative-stranded RNA. Plasmid F82D contains nucleotides
56 through 1149 from the 5' end of genomic RNA. Plasmid
F82N contains nucleotides 187 to 1989 from the 5' end of
genomic RNA. Both plasmids F82D and F82N produce
plus-stranded RNA from the T7 promoter.
Recombinant pT7 plasmids were transcribed in vitro by
using T7 RNA polymerase as previously described (5).
Briefly, transcription was carried out in 100 RI of reaction
buffer containing approximately 2 ,ug of linearized plasmid
DNA; 40 mM Tris hydrochloride (pH 7.5); 6 mM MgCl2; 2
mM spermidine; 10 mM NaCl; 10 mM dithiothreitol; 1 mM
each of ATP, CTP, and GTP; 0.01 mM UTP; 100 p,Ci of
[a-32P]UTP; 10 U of T7 RNA polymerase (Boehringer
Mannheim Biochemicals, Indianapolis, Ind.); and 40 U of
RNasin ribonuclease inhibitor (Promega Biotec, Madison,
Wis.). Reaction mixtures were incubated at 37°C for 1 h.
DNA templates were removed by digestion with 2 U of
RNase-free DNase I (New England Nuclear Corp., Boston,
Mass.) for 30 min at 37°C. RNA products were extracted
twice with phenol:chloroform (1:1) and precipitated with
ethanol at -20°C overnight.
Northwestern blot analysis. RNA binding proteins were
detected by the procedure described by Robbins et al. (26).
Briefly, the proteins in nucleus-free lysates of infected and
uninfected DBT cells were separated by electrophoresis on
10% sodium dodecyl sulfate-polyacrylamide gel electropho-
resis as previously described (32, 33). Each gel contained a
lane of [35S]methionine-labeled infected-cell lysate to local-
ize the N protein (32, 33). After polyacrylamide gel electro-
phoresis the separated proteins were transferred to nitrocel-
lulose paper (0.22 ,um, Bio-Rad Laboratories, Richmond,
Calif.) at 14 V overnight without cooling in a buffer contain-
ing 25 mM Tris, 192 mM glycine (pH 8.3), and 20% metha-
nol. Blots were stored -20°C.
Before assay, the blots were washed for 30 min in SBB
buffer (10 mM Tris [pH 7.0] containing 50 mM NaCl, 1 mM
EDTA, 0.02% bovine serum albumin, 0.02% Ficoll, and
0.02% polyvinyl pyrrolidone). Strips (0.5 cm) of the blots
were placed in test tubes (2025, Becton Dickinson) contain-
ing 4 ml of SBB and approximately 2 x 105 cpm of 32p_
labeled RNA, extracted from either virus-infected cells or in
vitro transcription products. Competitor RNA (total cyto-
plasmic RNA from uninfected cells) was added at various
concentrations to demonstrate the specificity of binding.
Amounts of competitor RNA represented a 103 and 104
molar excess relative to the probes tested. After 1 h at room
temperature with constant agitation, the strips were washed
with three changes of SBB and dried, and the bound RNA
was visualized by autoradiography.
Western blots (immunoblots). N protein was also localized
on the nitrocellulose paper strips by Western blotting anal-
ysis. Briefly, 0.5-cm nitrocellulose strips were washed in
buffer containing 10 mM Tris (pH 8.0) containing 150 mM
NaCl, 1 mM EDTA, and 0.5% Triton X-100 for 15 min at
room temperature and then incubated overnight in the same
buffer containing 3% bovine serum albumin at 4°C. The
strips were placed in test tubes as described above with 4.0
ml of buffer containing 3% bovine serum albumin and
monoclonal antibody A.1.10, specific for the N protein (15),
and incubated overnight at 4°C with constant agitation. The
antibody was removed, and the strips were washed at least
three times before the addition of 1.0 RCi of 125I-labeled
Staphylococcus A protein (ICN). After overnight incubation
at 4°C with constant agitation, the strips were washed at
least four times with 10 mM Tris buffer (pH 8.0) containing
1.0 M NaCl, 1.0 mM EDTA, 0.5% Triton X-100, and 3%
bovine serum albumin. The strips were dried, and the bound125I was visualized as described above.
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RESULTS
Specificity of the virus RNA-N protein interaction. The data
presented in the accompanying article suggest that there is a
specific interaction between the N protein and MHV RNA
on the basis of the specific coimmunoprecipitation of virus
RNA in complexes formed by the N protein and anti-N
monoclonal antibody (5). The data further suggest that the N
protein-RNA interaction is mediated, at least in part, by the
sequences present in the MHV leader RNA sequences. To
explore the specificity of the N protein-MHV RNA interac-
tion and to develop an approach that would allow us to more
clearly map the N binding site, RNA binding proteins in
infected and uninfected cells were examined by Northwest-
ern blot analysis (9, 26). Lysates of MHV-infected and
uninfected cells were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and transferred to nitro-
cellulose paper. The position of the N protein was verified by
Western blot analysis of adjacent lanes in all experiments. In
the initial experiments, 32P-labeled MHV-specific RNA was
extracted from infected actinomycin D-treated cells and
used as a probe in the binding assays. We sought to
determine whether the N protein-RNA binding previously
described (26) exhibited the high-affinity binding character-
istics of other sequence-specific nucleic acid-binding pro-
teins by using competitor RNA to distinguish between high-
and low-affinity binding (9, 14).
RNA extracted from MHV-infected cells, containing all
seven MHV RNA species (18, 31), binds to the MHV N
FIG. 2. Northwestern blot analysis of MHV-intracellular RNA
in the presence of competitor RNA. (A) Lanes: 1 and 2, binding of
MHV-RNA to the proteins in uninfected (lane 1) and infected (lane
2) cells in the absence of competitor RNA; 3 (uninfected cells) and
4 (infected cells), residual binding to N in the presence of 100 ,ug of
competitor RNA per ml. (B) Titration of the competitor RNA levels,
demonstrating the specificity of N-RNA binding. None, Absence of
competitor RNA.
protein as well as to a variety of proteins derived from the
cytoplasm of both uninfected and infected cells (Fig. 2A,
lanes 1 and 2, respectively). To determine the relative
affinity of binding of MHV RNA to the host cell-derived
RNA-binding proteins, RNA prepared from uninfected DBT
cells was used as a competitor. Competitor RNA (100 ,ug/ml)
effectively inhibited the binding of MHV RNA to the host
cell proteins but not to the N protein (Fig. 2A, lanes 3 and 4).
Densitometric analysis indicated approximately 20% reten-
tion of binding of viral RNA to N at 100 l.g of competitor
RNA per ml, whereas there was less than 1% retention of
binding to host cell RNA-binding proteins. Hence, this study
demonstrates that viral RNA is bound specifically by the N
protein and provides a useful approach for mapping binding
signals within the MHV genome.
Similar results were obtained with individual MHV
mRNAs 1, 6, and 7 isolated from infected cells and separated
by agarose gel electrophoresis (data not shown). The use of
specific MHV RNAs confirmed the presence of specific
binding sites on all MHV RNAs, as suggested by the
immunoprecipitation data presented in the accompanying
article (5). In addition, we determined that mouse liver
RNA, as well as L2 cell RNA, was a source of effective
competitor RNA, while Escherichia coli rRNA and yeast
tRNA were not effective competitors (data not shown). In
separate assays, we demonstrated that double-stranded
DNA also failed to compete with N-protein binding to viral
leader sequences (L. M. Welter, unpublished results).
To more clearly demonstrate specificity of binding, com-
petitor RNA was tested over a wide range (75 to 0.5 ,ug/ml)
for its ability to quantitatively inhibit binding of viral RNA to
the host cell RNA-binding proteins relative to N. The
binding of MHV RNA to host cell proteins can be signifi-
cantly reduced by the presence of 75 p.g of competitor RNA
per ml, and this binding changes in a dose-dependent manner
(Fig. 2B). In contrast, the binding to N protein was relatively
unaffected by the presence of competitor RNA, suggestive
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FIG. 3. Specific N-protein binding to in vitro RNA transcripts. (A) Specific binding ofRNA transcripts from plasmid F82P in the presence
of competitor RNA. (B) Absence of specific N binding by using a plasmid F82P RNA transcript in the negative sense. (C) Absence of specific
N binding the RNA transcribed from plasmid F82P linearized at the Xho site 5' of the MHV cDNA insert. None, Absence of competitor RNA.
of a specific and high-affinity binding. Therefore, these data
confirm the specificity of the N protein-MHV RNA interac-
tion demonstrated in the accompanying article (5).
Polarity-specific binding. The data in the accompanying
article show that anti-N monoclonal antibody immunopre-
cipitates negative-stranded RNA (5). We suggested that this
was due to the presence of N associated with the leader-
containing nascent plus-strands on the RI RNA. However,
we could not determine whether the negative-stranded
RNA, as part of the RI complex, binds N via interaction with
leader RNA sequences on the nascent plus-strands or
whether N was associated with the transcription complex via
protein-protein interactions. To determine whether an N
binding site is present on plus- and negative-sense MHV
RNA sequences, we first tested a 1.2-kilobase plus-sense
leader-containing in vitro RNA transcript derived from the 5'
end of the MHV genome (F82+) (Fig. 1) for high-affinity
binding to N. Figure 3A shows specific binding of this
leader-containing transcript to the N protein. A second band
of N, which migrates at a faster apparent molecular weight,
was detected in some lysates (Fig. 2 and 3; see also Fig. 5).
This band reacted with some, but not all, anti-N monoclonal
antibodies (data not shown). Whether this species represents
a degradation product or altered phosphorylated species is
unclear. In contrast to the specific binding of the leader-
containing transcript, the competitor RNA clearly inhibited
binding of an identical transcript in the negative-sense con-
figuration (Fig. 3B), as well as a transcript lacking MHV-
specific RNA sequences (Fig. 3C). These data indicate that
N binds to viral RNA via base sequence specific interactions
contained within plus-sense sequences at the 5' end of the
genome and that in vitro transcripts can be used to define the
N protein-RNA interaction. Conversely, negative-sensed
RNAs derived from the 5' end did not bind N. These data
suggest that the N protein does not directly associate with
negative-stranded RNA unless other binding sites are con-
tained elsewhere on the genomic-length negative-stranded
RNA species.
Binding by leader-containing RNAs. Small leader-con-
taining RNA species immunoprecipitated with anti-N mono-
clonal antibody suggested that the N-RNA binding site was
contained within the MHV leader RNA (5). To confirm the
direct binding ofN protein to the sequences contained within
the leader RNA, we examined in vitro transcripts prepared
from a pT7 plasmid containing an insert composed of the
leader sequences plus 18 additional nucleotides derived from
the 5' end of MHV mRNA 6 (Fig. 1). This plus-stranded
RNA bound to the N protein, and binding was not inhibited
in the presence of competitor RNA (Fig. 4A). Confirming the
requirements for polarity specificity, binding in the presence
of competitor RNA was not detected by using the negative-
sense 90-base transcript derived from plasmid E1-L'(-)
(Fig. 4B). These data support the findings presented in the
accompanying article and clearly indicate that an N-protein
binding site is present within the leader RNA sequence.
Localization of the binding site. In the accompanying
article (5) we demonstrate that N binds to the 65-nucleotide
but not the 57-nucleotide leader RNA, suggesting that these
leader RNA sequences are critical for N-RNA binding.
However, it is not clear whether sequence 5' to position 57
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FIG. 4. Specific N binding activity in positive- but not negative-sensed leader RNA transcripts. RNA transcripts from plasmid E1-L in the
positive (A) and negative (B) sense orientations were analyzed for their ability to bind N protein in the presence of various amounts of
competitor RNA. None, Absence of competitor RNA.
also participates as part of the N binding site. To further
localize the binding site, the plasmid E1-L'(+), containing
the 90-base leader insert, was digested with either the DraI
or the SnaBI restriction endonucleases before in vitro tran-
scription (Fig. 1). Digestion of this template with DraI yields
in vitro RNA transcripts containing the first 56 nucleotides at
the 5' end of leader RNA, while digestion with the SnaBI
endonuclease yields a 24-nucleotide 5' transcript. The sizes
and integrity of these transcripts were confirmed by electro-
phoresis on denaturing polyacrylamide gels (data not
shown). These truncated in vitro leader RNA transcripts do
not exhibit specific binding in the presence of competitor
RNA (Fig. SB and C). This can be compared with the
high-affinity binding detected with the full leader contained
within the 90-base transcript (Fig. SA). These data suggest
that the sequences exhibiting specific N binding require
nucleotides 56 through 90 in mRNA 6. To rule out specific
interactions with the 18 nucleotides 3' to leader sequences
derived from gene F which are contained in E1-L' (Fig. 1),
we examined transcripts derived from plasmid F82D con-
taining a cDNA insert representing nucleotides 56 through
1149 from the 5' end of genomic RNA (30). This cDNA clone
diverges from the mRNA 6 sequence at position 67 (28).
Specific high-affinity binding of this probe to the N protein in
the presence of competitor RNA was found by using RNA
transcribed from this plasmid (Fig. 5D). To confirm that no
cryptic sites were contained in this relatively long transcript,
we also tested a transcript derived from plasmid F82N
containing a cDNA insert of nucleotides 187 to 1989 from the
5' end of genomic RNA (Fig. 1) and found no specific binding
(Fig. 5E). It is unclear whether additional N binding se-
quences are present between nucleotides 67 and 187 in gene
A, which potentially provides a packaging signal for genomic
RNA.
RNA was also synthesized from a plasmid containing
internal nucleotides 90 to 609 from the 5' end of mRNA 6
(E1-500) which lacks the first 90 nucleotides tested for Fig.
4A. These internal sequences do not exhibit specific binding
to N (Fig. SF). Therefore, these data suggest that specific
and high-affinity binding of viral RNA by the N protein is
necessary and sufficiently supplied by nucleotides in the
viral leader spanning positions 56 to 67 of genomic RNA.
DISCUSSION
In the accompanying article we have demonstrated that
the MHV N protein binds not only to the positive-stranded
genomic-length RNA but also to all six subgenomic mRNAs
(5). This binding appears to be mediated by sequences
located at the 5' end of each mRNA. After infection, the
MHV genomic RNA is transcribed by an early polymerase
activity into a full-length negative-stranded RNA (10, 11,
19). Transcription of plus-stranded genomic-length RNA and
the six subgenomic-length RNAs that make up the nested set
of MHV mRNAs is via a unique leader-primed discontinu-
ous nonprocessive mechanism (8, 22). Evidence for this
mechanism includes the finding of free leader dissociated
from the negative-stranded template and a temperature-
sensitive mutant which synthesizes leader RNAs but not
mRNAs at the nonpermissive temperature (6, 8). The leader
RNA is also found at the 5' end of all positive-stranded MHV
RNAs, including the 5' ends of nascent RNA on the RI
J. VIROL.
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FIG. 5. Localization of the RNA binding site within the leader RNA sequence. (A) High-affinity binding by the RNA transcribed from
E1-L(+). (B) Absence of specific binding by RNA containing nucleotides 1 through 56. (C) Absence of specific binding by RNA containing
nucleotides 1 through 24. (D) Specific binding by RNA transcripts from plasmid F82D (nucleotides 56 through 1149). (E) Absence of specific
binding by RNA transcripts from plasmid F82N (nucleotides 187 through 1989). (F) Absence of specific binding by RNA transcripts from
plasmid E1-500 (nucleotides 90 through 609). None, Absence of competitor RNA.
complex (7, 17, 18). Further, the leader RNA sequences
reassort at high frequency during mixed infection, indicating
that these RNAs act in trans (21). The data presented in this
and the accompanying article suggest that an N binding site
is present within the MHV leader RNA sequence.
Negative-stranded as well as positive-stranded RNA is
coimmunoprecipitated with N protein (5), suggesting either
that N binds to negative-sensed RNA or that the leader-
containing nascent chains of the RI complex (7) were asso-
ciated with the N protein. The experiments described in this
article examined the possibility of N binding domains on the
negative-stranded RNA. Neither the 1.2-kilobase RNA tran-
script derived from the 5' end sequences of genomic RNA
nor the 90-base leader-containing RNA, both transcribed in
the negative-sense configuration, was bound to N with
specificity. In contrast, the complementary plus-sense RNA
derived from the 5' ends of both gene A and gene F
sequences showed specific high-affinity binding. These data
indicate that an N protein binding site is present on the
leader RNA sequences contained on the nascent plus-
strands of the RI complex (7) and further suggest a role for N
in the transcription complex, as previously suggested by the
inhibition of transcription by anti-N monoclonal antibody
(12). These data also suggest that if the N protein binds to
negative-stranded RNA, the interaction is mediated by se-
quences other than those at the 5' end.
Analysis of the small MHV-specific leader-containing
RNAs in infected cells by immunoprecipitation with anti-N
monoclonal antibody suggests that N was present on RNA
species greater than 65 nucleotides long (5). However, it
could not be determined whether N bound directly to leader
RNA sequences or whether it bound indirectly via associa-
tion with other viral RNA-binding proteins. We have used
RNAs produced by in vitro transcription to localize the site
of N protein binding to the leader RNA. Northwestern blot
analysis of high-affinity N-protein RNA binding in the pres-
ence of competitor RNA showed that N binds directly to the
90-base leader-containing RNA sequences derived from
gene F. Analysis of RNAs deleted for the bases 1 through 56
confirmed that the sequences 1 through 56 alone do not
exhibit high-affinity N binding. However, these data do not
rule out the possibility of a minor contribution from the
nucleotides 5' of nucleotide 56. In addition, specific binding
was demonstrated by using transcripts from the plasmid
C
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F82D, which contains nucleotides 56 through 1149 from the
5' end of genomic RNA (30). In contrast, plus-stranded
sequences derived from the body of gene F (plasmid E1-500)
or from the 5' end of genomic RNA (plasmid F82N), both of
which lacked the leader RNA sequences, did not show
demonstrable specific binding by the N protein (Fig. 5).
We have previously shown that the 3' end of leader RNA
contains a weak potential hairpin loop involving nucleotides
52 through 76 (28). The predicted N binding site corresponds
to sequences within this potential hairpin loop. Further, the
demonstration of N in the RI complex and on the free
leader-containing MHV-specific RNAs as well as the finding
that free leader RNA binds N suggests that N may play a role
in regulation of leader-primed transcription. We have no
direct evidence that an N-leader RNA complex is required
for subgenomic transcription other than the inhibition of
transcription by anti-N but not anti-El or anti-E2 monoclo-
nal antibodies (11; P. R. Brayton, unpublished data). In
addition, the precise length of the free leader RNA that
functions as primer is not known. However, we have sug-
gested that it may contain more than 72 nucleotides, on the
basis of homology with the negative-sense intergenic regions
preceeding genes E, F, and G (28). We have also suggested
that expression of the subgenomic mRNAs may be regulated
by the extent of the homology between the extended 3'
leader sequences derived from the 5' end of the genomic
RNA and the intergenic regions (28). For example, the
homology between leader RNA and the intergenic region of
mRNA 7, the most abundant viral mRNA, covers 18 bases
between nucleotides 63 and 81. These data suggest that such
an RNA will have a functional N binding site. Therefore, a
possible function for N in transcription may be to prevent
base pairing at this potential hairpin loop and obviate the
need to overcome the energy requirement to linearize the
leader RNA before binding to the intergenic transcriptional
start sites. An alternate possibility is suggested by the
cytoplasmic small free leader-containing RNAs. These
RNAs are believed to represent functional transcriptional
intermediates (6) that may participate in the high-frequency
RNA-RNA recombinational events described during coro-
navirus replication (22). N binding to leader transcripts of
sufficient length to contain the specific binding site, i.e.,
longer than 72 nucleotides, may serve to target these RNA-
protein complexes to the transcription complex through
protein-protein interactions. This is supported by our finding
that anti-N monoclonal antibody immunoprecipitates nega-
tive-stranded RNA from the membrane fraction (5), the site
of RNA polymerase activity in infected cells (10, 11). Fi-
nally, our data cannot rule out the possibility that the binding
of N and its subsequent self-assembly on the nascent strands
may serve to prevent RNA-RNA base pairing after tran-
scription.
We have tentatively localized the N-RNA binding site
between nucleotides 56 and 65 in the leader RNA; therefore,
it is not surprising that the subgenomic viral mRNAs are
bound in ribonuclear protein complexes. Similar complexes
involving mRNAs that are not packaged into virions have
been identified during both vesicular stomatitis virus and La
Crosse virus replication (4, 25, 27). These data suggest that
additional cis-acting sequences must be present in the MHV
genome to ensure efficient encapsidation of the genomic
RNA. Alternatively, either a size constraint permitting only
encapsidation of full-length genomic RNA or subcellular
compartmentalization of genomic RNA may be required for
proper packaging. The first two possibilities are supported
by studies characterizing the defective interfering RNAs of
MHV, which contain leader RNA sequences as well as
internal deletions and rearrangements in the internal se-
quences (21). Only the RNA designated DIssA is packaged
into virions, while the smaller defective interfering RNAs of
MHV are not (21). This may be due either to the lack of
additional packaging signals or to size constraints placed
upon nucleocapsid formation requiring a full-length or nearly
full-length genomic RNA. Interestingly, Rous sarcoma virus
and Moloney murine leukemia virus appear to have at least
two sites for encapsidation (23) which coordinate in provid-
ing genomic RNA with the proper specificity required for
efficient packaging. In addition, while vesicular stomatitis
virus mRNAs associate with its N protein in infected cells,
only the genome-length RNA and leader RNA are encapsi-
dated (3, 4, 16). The third possibility is suggested by the
separation of the MHV-induced polymerases (11). The en-
zymatic activity synthesizing genomic-length RNA is asso-
ciated with a population of cellular membranes that differ in
density from those associated with the polymerase activity
synthesizing virus-specific mRNA (11). These data suggest
that encapsidation is a complex process which involves a
variety of factors and that the presence of bound N protein
may be insufficient to provide the appropriate packaging
signal(s).
Several models are used to describe the structure ofDNA
protein interactions, such as the helix-turn-helix model ex-
emplified by the lambda repressor and the zinc-binding
fingers of the glucocorticoid receptor (1, 24). The manner in
which proteins bind RNAs is less predictable, because of
their less ordered secondary and tertiary structures. The
complete gene sequence of the N protein has been deter-
mined (3, 29), and a search of the predicted protein sequence
does not reveal obvious paradigms for nucleic acid binding.
It is our current goal to rigorously define the nucleic acid
binding including domains of the N protein by site-directed
mutagenesis.
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